Çѱ¹¹ÙÀÌ¿ÀÀǾàÇ°Çùȸ¿¡¼ ¾È³»µå¸³´Ï´Ù.
<BIO KOREA 2022 ÇÑ-È£ÁÖ ÆÄÆ®³Ê¸µ ¼ö¿äÁ¶»ç ¾È³»>
2022³â 5¿ù 11ÀÏ ºÎÅÍ °³ÃֵǴ BIO KOREA¿¡¼ ÇÑ-È£ÁÖ ÆÄÆ®³Ê¸µÀÌ ÀÖÀ» ¿¹Á¤ÀÔ´Ï´Ù. °ü·ÃÇÏ¿© È£ÁÖÀÇ ÆÄÆ®³Ê¸µ Âü°¡»ç¸¦ ¾È³»µå¸®¿À´Ï, °ü½É ÀÖÀ¸½Å ±â¾÷ °ü°èÀÚ ºÐµé²²¼´Â Èñ¸ÁÇÏ´Â ¾÷üÀÇ ¸íÀ» info@kobia.kr ¶Ç´Â juliet.woo@austrade.gov.au À¸·Î ȸ½ÅÇÏ¿© Áֽñ⠹ٶø´Ï´Ù.
¡¤
CRO / Clinical trial site
NO
|
Company
|
Business
Area
|
Technology/Service
|
Âü°¡ÇüÅÂ
|
¹ÌÆÃÈñ¸Á¿©ºÎ
|
1
|
360biolabs
|
ÀÓ»ó¼öŹ¿¬±¸±â°ü- PK/PD ½ÃÇè µî ¹ÙÀÌ¿À ºÐ¼® ¹× Áß¾Ó ½ÇÇè½Ç ¼ºñ½º
|
Leading contract research organization.
Specializing in small molecules, large molecules and vaccines.
Providing a single solution for global clinical trial requirements with
laboratories in USA and Europe as well as Australia.
|
ÇöÀå Âü°¡
|
|
2
|
CMAX
|
ÃʱâÀÓ»ó Àü¹® »çÀÌÆ®
|
Early phase clinical trials with 66 inpatient
beds and located adjacent to Adelaide¡¯s Bio-Med City, providing access to
state-of-the-art facilities, equipment and world-class medical and
pharmacology specialists.
|
¿Â¶óÀÎ Âü°¡
|
¡¡
|
3
|
George Clinical
|
¾ÆÅÂÁö¿ª ¹× ¹Ì±¹º£À̽ºÀÇ Àü´Ü°è Á¦¾à∙¹ÙÀÌ¿À∙ÀÇ·á±â±â Àü¹® CRO
|
Provides the full range of clinical trial
services to biopharmaceutical, medical device, and diagnostic customers, for
all trial phases, registration and post-marketing trials
|
ÇöÀå Âü°¡
|
¡¡
|
4
|
Novotech
|
Àü´Ü°è ÀüÄ¡·áºÐ¾ß ÀÓ»ó°³¹ß Àü¹® CRO
|
Providing all clinical trial phases services
and therapeutic areas including: feasibility assessments; ethics committee
and regulatory submissions, data management, statistical analysis, medical
monitoring, safety services, central lab services, report write-up to ICH
requirements, project and vendor management.
|
ÇöÀå Âü°¡
|
¡¡
|
5
|
Nucleus Network Pty Ltd
|
ÃʱâÀÓ»ó Àü¹® ¸ÖƼ ÀÓ»ó»çÀÌÆ®
|
Australia¡¯s largest Phase 1 clinical research
organization with facilities in the USA and Australia offering over 200 beds.
All three clinics are strategically co-located within the Alfred Hospital in
Melbourne, the Royal Brisbane and Women¡¯s Hospital in Brisbane, and Medical
Alley in Minnesota.
|
ÇöÀå Âü°¡ (¹ÌÈ®Á¤)
|
¡¡
|
6
|
Opyl
|
AI ±â¼úÀ» ÀÌ¿ëÇÑ ÀÓ»ó½ÃÇè ȯÀÚ¸ðÁý Ç÷§Æû
|
AI empowered clinical trial recruitment
platform and patient database that leverages social media channels to attract
and match participants to study opportunities located anywhere in the world
and in languages other than English.
|
ÇöÀå Âü°¡
|
|
7
|
Scientia Clinical
Research
|
ÃʱâÀÓ»ó Àü¹® ÀÓ»ó »çÀÌÆ®
|
Not-for-profit early phase clinical trial
company operating 30-bed phase I unit co-located within the Prince of Wales
Hospital a tertiary teaching hospitals offering a full range of clinical
specialties.
|
ÇöÀå Âü°¡
|
|
8
|
Southern Star Research
|
Á¦¾à∙¹ÙÀÌ¿À∙ÀÇ·á±â±â Ãʱâ ÀÓ»ó Àü¹® CRO
|
A leading Australian, privately owned,
full-service CRO specialising in early phase clinical research support to
biotech, device and pharmaceutical sponsors. Actively support Ph
I/II studies in Australia and New Zealand and Ph II/III projects in South
East Asia, Europe and the US.
|
ÇöÀå Âü°¡
|
¡¡
|
¡¤
CMO /
CDMO
NO
|
Company
|
Business
Area
|
Technology/Service
|
Âü°¡ÇüÅÂ
|
¹ÌÆÃÈñ¸Á¿©ºÎ
|
1
|
Luina Bio
|
½ÃÇè¾à Á¦Á¶ ¹× »ó¾÷ »ý»ê ÀǾàÇ°¼öŹ°³¹ß, Á¦Á¶ ¹× ±ÔÁ¦ °ü·Ã ¼ºñ½º
|
Carries out microbial aerobic and anaerobic
fermentation (BSL1 and BSL 2), technical transfer, cell banking, process
development and validation, analytical development, GMP production and
stability studies
|
ÇöÀå Âü°¡
|
¡¡
|
¡¤
Consulting
NO
|
Company
|
Business
Area
|
Technology/Service
|
Âü°¡ÇüÅÂ
|
¹ÌÆÃÈñ¸Á¿©ºÎ
|
1
|
Acclime Australia
|
È£ÁÖ ÀÓ»ó½ÃÇè µî R&D ¼¼Á¦ ÇýÅà ÀÚ°Ý ¿ä°ÇÀÎ ¹ýÀÎ ¼³¸³¿¡ °üÇÑ ÄÁ¼³Æà Á¦°ø
|
Supporting foreign life science companies
that are entering the Australian market to conduct R&D and access the
Federal government¡¯s R&D Tax Incentive. Providing solution to expand to
Australia or to the USA, either as a virtual company or a fully operational
physical office.
|
ÇöÀå Âü°¡
|
¡¡
|
2
|
Bentleys R&D Tax
Incentives
|
È£ÁÖ ÀÓ»ó½ÃÇè µî R&D ¼¼Á¦ ÇýÅÃ
ÀÚ°Ý ¿ä°ÇÀÎ ¹ýÀÎ
¼³¸³¿¡ °üÇÑ ÄÁ¼³ÆÃ
Á¦°ø
|
Delivers a best practice, full service and low-cost
solution for non-Australian controlled Biotech/MedTech enterprises seeking to
create a corporate presence in Australia and make use of the R&D Tax
Incentive.
|
¿Â¶óÀÎ Âü°¡
|
|
¡¤
Biotech
NO
|
Company
|
Business
Area
|
Technology/Service
|
Âü°¡ ÇüÅÂ
|
¹ÌÆÃÈñ¸Á¿©ºÎ
|
1
|
Biome Bank
|
¸¶ÀÌÅ©·Î¹ÙÀÌ¿È Ä¡·áÁ¦ °³¹ß Àü¹®
|
Platform which combines a unique ability to
culture gut microbes with bioinformatics capabilities for discovery of
microbial biomarkers, leads, and targets.
|
¿Â¶óÀÎ Âü°¡
|
¡¡
|
2
|
Microba
|
¸¶ÀÌÅ©·Î¹ÙÀÌ¿ÈÀ» ÀÌ¿ëÇÑ ÀǾàÇ° ¿¬±¸°³¹ß ¹× ºÐ¼®À» ÅëÇÑ Ä¡·á ¼Ö·ç¼Ç °³¹ß
|
A precision microbiome science company taking
a human-first, data-driven approach to therapeutic discovery. Discovering
medically-relevant biomarkers from the microbiome to transform human health.
|
ÇöÀå Âü°¡ (¹ÌÈ®Á¤)
|
¡¡
|
3
|
PYC Therapeutics
|
Cell-Penetrating Peptide technology and
PMO-design technology (PPMOs) Ç÷§Æû ±â¼úÀ» ÀÌ¿ëÇÑ RNA Ä¡·áÁ¦
°³¹ß
|
A pioneer in the world of RNA biology and
PMOs, co-invented the first approved PMO, Exondys51, a treatment for Duchenne
muscular dystrophy. PYC are designing the next generation of life-altering
PMO therapeutics — including our lead drug candidate, VP-001.
|
¿Â¶óÀÎ Âü°¡
|
|
4
|
Regeneus
|
Ÿ°¡Áö¹æ À¯·¡Áß°£¿± Áٱ⼼Æ÷¸¦ ÀÌ¿ëÇÑ ¼¼Æ÷ ÀǾàÇ° ¿¬±¸ °³¹ß
|
Progenza¢â: allogeneic MSCs and bioactive
secretome product for knee osteoarthritis
Sygenus¢â: MSC bioactive secretome product with broad topical therapeutic
applications
|
ÇöÀå Âü°¡
|
¡¡
|
¡¤
Medtech
NO
|
Company
|
Business
Area
|
Technology/Service
|
Âü°¡ ÇüÅÂ
|
¹ÌÆÃÈñ¸Á¿©ºÎ
|
1
|
Avicena Systems
|
½Å¼Ó ÃÊ°íÈ¿À² ½ºÅ©¸®´× ºÐÀÚ ºÐ¼®±â
|
A revolutionary molecular assay instrument to
screen for pathogens, capable of undertaking 3,840 isothermal assays per hour
(peak throughput) per instrument in real-life conditions with 35 minutes
total processing time per assay.
|
¿Â¶óÀÎ Âü°¡
|
¡¡
|
2
|
Inventia
Life Science
|
3D cell culture ¹ÙÀÌ¿À
ÇÁ¸°ÆÃ
|
Inventia Life Science is advancing 3D cell culture
technology to bioprint human cells in 3D and help forward-thinking pioneers
in the fields of drug discovery and biomedical research to create human
tissue for research and therapy.
|
¿Â¶óÀÎ Âü°¡
|
|
¡¤
Medical Research Institute
NO
|
Company
|
Business
Area
|
Technology/Service
|
Âü°¡ ÇüÅÂ
|
¹ÌÆÃÈñ¸Á¿©ºÎ
|
1
|
University of Queensland
|
R&D Á᫐ ´ëÇÐ ¿¬±¸±â°ü
|
UQ is home to 8 institutes, including the
Australian Institute for Bioengineering and Nanotechnology (AIBN). AIBN is
home to a critical mass of facilities and world-class experts providing
development and translational services around recombinant products, including
proteins and nucleic acids such as mRNA.
|
ÇöÀå Âü°¡
|
¡¡
|
2
|
QIMR Berghofer Medical
Research Institute
|
R&D, Áß°³¿¬±¸, ¿¬±¸¼ºñ½º ±â°ü
|
One of Australia¡¯s largest and most successful institutes
with focus on translating scientific discoveries into novel therapeutics and
diagnostics for oncology, infectious, immunological, and neurological
diseases. QIMR Berghofer partner with companies and investors to develop and
bring our innovative clinical solutions to market.
|
ÇöÀå Âü°¡
|
¡¡
|
|
|